Democratic candidates had their eye on business and the working class during the first Democratic presidential debate in Miami.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
These attacks have given the public the opportunity to examine the problems associated with ransomware, where corporations -- not obligated to disclose these attacks -- have...Technologyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
Roche shares tumbled to rank among the worst performers in European trade on Monday following news of the failure of trials for its skin cancer treatment Zelboraf. The disappointing results came alongside confirmation that similar products from compatriot and rival Novartis had met their aims.
Roche shares were trading 1.35 percent underwater by 12:30 p.m. London time as analysts considered the implication for the company in light of the separate recent trial failure of the company's eye treatment lampalizumab.
The fact that the disappointment is the second notable failure from the Genentech stable – the R&D business that was acquired in 2009 and is run as an independent entity within the Swiss pharma giant alongside Roche's own R&D unit – is concerning, John Rountree, partner at Novasecta, told CNBC on Tuesday.
"This is another blow and people will start to question that ability of that part of the organization to deliver really quality development," he highlighted, adding that analysts will need to reconsider the overall company's sales forecasts.
The failure comes as Roche's dependence on generating new blockbusters grows given the gateways now open to competitors to develop cheaper copies of its effective cancer drugs Herceptin, Avastin and Rituxan, which together deliver around $20 billion worth of sales per year.
Yet despite the hitches, Rountree believes the company's policy of allocating significant funding to R&D will see Roche through the bumpy waters.
"I think they've got a viable strategy. They're continuing to innovate and they're investing a lot in R&D...the biosimilar (an almost identical biologic copy of an original drug) is a threat to them and they've just got to work harder. You're going to get trial setbacks but they've just got to keep ploughing ahead with that innovation," he argued.
Anticipating that sales projections for the company are likely to be "a little bit down but not horrendously", the partner at the pharmaceutical consultancy said the financial firepower of the Swiss giant would stand it in good stead going forward.
"Each one (trial failure) is going to damage the forecast but I think the bigger picture is that there's an enormous machine going on to innovate and people I would argue don't bet against Roche, they've got a lot of history," he said, even as investment bank Goldman Sachs sliced the company's price target by 10 swiss francs to 325 swiss francs.
"They've got the double power of R&D compared to a lot of other big pharmaceuticals."